| Q61886048 | A History of the Pharmacological Treatment of Bipolar Disorder |
| Q37326130 | A UK consensus on the administration of aripiprazole for the treatment of mania |
| Q43045861 | A nearly overlooked mild case of ziprasidone-induced lingual dystonia. |
| Q39880014 | A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. |
| Q35236966 | Acute and long-term treatment of mania. |
| Q35618427 | Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics |
| Q36649096 | Acute treatment of mania: an update on new medications |
| Q36905879 | Adjunctive treatment of acute mania: a clinical overview |
| Q37933405 | Adverse Drug Events Related to Ziprasidone: A Meta-analysis of Randomized, Placebo-Controlled Trials |
| Q51857910 | Algorithm-driven treatment for bipolar disorder in Korea: Clinical feasibility, efficacy, and safety. |
| Q48908840 | An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses |
| Q40176997 | An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. |
| Q34553398 | Anticonvulsants and antipsychotics in the treatment of bipolar disorder |
| Q36407359 | Anticonvulsants in the treatment of bipolar mania |
| Q38884279 | Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management |
| Q37111491 | Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review |
| Q46886132 | Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study |
| Q36026701 | Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. |
| Q37781370 | Atypical antipsychotic tolerability and switching strategies in bipolar disorder |
| Q36797200 | Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights |
| Q21260276 | Atypical antipsychotics in bipolar disorder: systematic review of randomised trials |
| Q36158824 | Atypical antipsychotics: newer options for mania and maintenance therapy |
| Q38003196 | Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder |
| Q57738604 | Behandlungsmöglichkeiten der akuten Manie mit atypischen Antipsychotika |
| Q36296403 | Best clinical practice with ziprasidone IM: update after 2 years of experience. |
| Q33448290 | Bipolar disorder. |
| Q36390795 | Bipolar disorder: historic perspective, current pharmacologic treatment options and a review of quetiapine |
| Q52656684 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. |
| Q34809427 | Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? |
| Q38211511 | Clinical decision making in the treatment of mixed states |
| Q37100104 | Comparison of mania patients suitable for treatment trials versus clinical treatment |
| Q28686902 | Current and emerging therapies for the management of bipolar disorders |
| Q36488206 | Current schizophrenia drugs: efficacy and side effects |
| Q36905876 | Depot antipsychotic medications in bipolar disorder: a review of the literature |
| Q38586755 | Diagnosis, Epidemiology and Management of Mixed States in Bipolar Disorder |
| Q37844574 | Drug safety evaluation of ziprasidone |
| Q37254782 | Drug-induced hyperphagia: what can we learn from psychiatric medications? |
| Q36274272 | Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review |
| Q35238333 | Effect of initial ziprasidone dose on treatment outcome of korean patients with acute manic or mixed episodes |
| Q38003197 | Efficacy of antimanic treatments in mixed states |
| Q24601815 | Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials |
| Q35999567 | Efficacy of atypical antipsychotics in bipolar disorder |
| Q34994544 | Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q37244172 | Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder |
| Q36634257 | Emerging drugs for bipolar disorder |
| Q36364980 | Emerging treatments for bipolar disorder: safety and adverse effect profiles |
| Q36881398 | Epidemiology, diagnosis and management of mixed mania |
| Q33518314 | Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials |
| Q38284625 | Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder |
| Q48249859 | Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults |
| Q53444102 | Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. |
| Q36588607 | Evidence review and clinical guidance for the use of ziprasidone in Canada |
| Q46984808 | Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials |
| Q53080275 | Factors modifying drug and placebo responses in randomized trials for bipolar mania. |
| Q37763161 | Health-related quality of life and functioning in bipolar disorder: the impact of pharmacotherapy |
| Q37983600 | Health-related quality of life in bipolar disorder |
| Q39049252 | Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder? |
| Q33529314 | Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis |
| Q37404584 | Lithium therapy and hyperparathyroidism: an evidence-based assessment |
| Q36284465 | Management options for bipolar disorder in children and adolescents |
| Q37696241 | Mixed episodes with psychotic features. |
| Q38833165 | Mixed states in bipolar disorder - changes in DSM-5 and current treatment recommendations |
| Q36119897 | Mood stabilization in the treatment of bipolar disorder: focus on quetiapine |
| Q35872066 | New medication treatment options for bipolar disorders |
| Q37954390 | Obesity and psychotropics. |
| Q37960632 | Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review |
| Q36349023 | Pharmacological treatment of mixed states |
| Q46185243 | Pharmacotherapy in bipolar disorders during childhood and adolescence |
| Q37742068 | Pharmacotherapy of bipolar disorder in children and adolescents: recent progress |
| Q36130303 | Pharmacotherapy of bipolar mixed states |
| Q44017165 | Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania |
| Q36361982 | Polytherapy in bipolar disorder |
| Q30571258 | Posttraumatic stress disorder, depression, and health-related quality of life in patients with bipolar disorder: review and new data from a multi-site community clinic sample |
| Q37908140 | Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder |
| Q35746806 | Psychiatric medication-induced obesity: a review |
| Q36648780 | Psychopharmacology of pediatric bipolar disorder: a review |
| Q35613754 | Psychotic bipolar disorders: dimensionally similar to or categorically different from schizophrenia? |
| Q24643545 | Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder |
| Q38296631 | QT Interval Prolongation Associated with Intramuscular Ziprasidone in Chinese Patients: A Case Report and a Comprehensive Literature Review with Meta-Analysis |
| Q35875975 | Quality of life among bipolar disorder patients misdiagnosed with major depressive disorder |
| Q35547289 | Recent developments in the treatment of bipolar disorders |
| Q37954423 | Refractoriness in bipolar disorder: definitions and evidence-based treatment |
| Q46744416 | Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic |
| Q36780394 | Risperidone versus risperidone plus sodium valproate for treatment of bipolar disorders: a randomized, double-blind clinical-trial |
| Q35618441 | Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. |
| Q36199036 | Safety and tolerability of emerging pharmacological treatments for bipolar disorder |
| Q37202889 | Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder. |
| Q37775630 | Strategies for successful clinical management of schizophrenia with ziprasidone |
| Q47642128 | The Black Book of Psychotropic Dosing and Monitoring |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q34606256 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania |
| Q34649187 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder |
| Q35775218 | The case for atypical antipsychotics in bipolar disorder |
| Q38003199 | The clinical management of bipolar disorder complexity using a stratified model |
| Q37292350 | The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges. |
| Q38132709 | The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study |
| Q35779335 | The pharmacology of bipolar disorder during pregnancy and breastfeeding |
| Q45070780 | The risk of harm in mania and the very early time course of improvement: important but neglected variables in treatment research |
| Q37873301 | The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder |
| Q36979293 | The use of antipsychotics in children and adolescents with bipolar disorders |
| Q37468555 | The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder |
| Q42164457 | Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials |
| Q37429721 | Treating bipolar disorder in the primary care setting: the role of aripiprazole |
| Q39048607 | Treating mixed mania/hypomania: a review and synthesis of the evidence |
| Q35673093 | Treatment of acute mania |
| Q36162402 | Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder |
| Q37973144 | Treatment of mixed bipolar states |
| Q44797813 | Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? |
| Q37171035 | Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. |
| Q34557537 | Weight gain, obesity, and psychotropic prescribing |
| Q39037156 | Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine |
| Q34581055 | Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. |
| Q36938311 | Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder |
| Q44756176 | Ziprasidone in Parkinson's disease psychosis |
| Q37244876 | Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study |
| Q83866936 | Ziprasidone in bipolar disorder |
| Q46202394 | Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study |
| Q37336886 | Ziprasidone in the treatment of affective disorders: a review. |
| Q34966022 | Ziprasidone in the treatment of mania in bipolar disorder |
| Q36558654 | Ziprasidone: efficacy and safety in patients with bipolar disorder |
| Q30984472 | Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness |
| Q81395902 | [Atypical antipsychotics and metabolic syndrome] |